Literature DB >> 32072470

New Developments in the Diagnosis and Management of Gastroesophageal Reflux.

Yan Jiang1, John O Clarke2,3.   

Abstract

PURPOSE OF REVIEW: To examine recent key developments in the pathophysiology, diagnosis, and treatment of gastroesophageal reflux disease (GERD). RECENT
FINDINGS: Newer research has suggested cytokine-mediated inflammation may play a role in the physiology of GERD, implying that the underlying mechanism may not be entirely related to chemical damage due to acid. Aided by novel technologies, diagnostic testing is also moving toward elucidating individual mechanisms and better defining specific GERD phenotypes with the goal of providing directed therapy. This is especially important in current times given the increase in coverage of adverse events reportedly linked to long-term proton pump inhibitor use. As patients are looking for potential alternatives, we highlight the key recent updates in pathophysiology and understanding of GERD and current medical and endoscopic/surgical options and explore the exciting treatments in the pipeline.

Entities:  

Keywords:  Functional lumen imaging probe (FLIP); GERD; Gastroesophageal reflux disease; Linx

Year:  2020        PMID: 32072470     DOI: 10.1007/s11938-020-00275-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  42 in total

1.  Circumferential EMR of carcinoma arising in Barrett's esophagus: case report.

Authors:  Hitoshi Satodate; Haruhiro Inoue; Tatsuya Yoshida; Shinsuke Usui; Michiaki Iwashita; Norio Fukami; Akira Shiokawa; Shin-ei Kudo
Journal:  Gastrointest Endosc       Date:  2003-08       Impact factor: 9.427

Review 2.  No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis.

Authors:  Seth Lipka; Ambuj Kumar; Joel E Richter
Journal:  Clin Gastroenterol Hepatol       Date:  2014-10-18       Impact factor: 11.382

Review 3.  Complications of Proton Pump Inhibitor Therapy.

Authors:  Michael F Vaezi; Yu-Xiao Yang; Colin W Howden
Journal:  Gastroenterology       Date:  2017-05-19       Impact factor: 22.682

4.  Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury.

Authors:  Rhonda F Souza; Xiaofang Huo; Vivek Mittal; Christopher M Schuler; Susanne W Carmack; Hui Ying Zhang; Xi Zhang; Chunhua Yu; Kathy Hormi-Carver; Robert M Genta; Stuart J Spechler
Journal:  Gastroenterology       Date:  2009-08-04       Impact factor: 22.682

Review 5.  Utility of esophageal mucosal impedance as a diagnostic test for esophageal disease.

Authors:  Dhyanesh A Patel; Michael F Vaezi
Journal:  Curr Opin Gastroenterol       Date:  2017-07       Impact factor: 3.287

6.  Measurement of esophago-gastric junction cross-sectional area and distensibility by an endolumenal functional lumen imaging probe for the diagnosis of gastro-esophageal reflux disease.

Authors:  E Tucker; R Sweis; A Anggiansah; T Wong; E Telakis; K Knowles; J Wright; M Fox
Journal:  Neurogastroenterol Motil       Date:  2013-08-26       Impact factor: 3.598

7.  A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility.

Authors:  Nitin Aggarwal; Prashanthi Nagavenkata Thota; Rocio Lopez; Scott Gabbard
Journal:  Neurogastroenterol Motil       Date:  2017-09-08       Impact factor: 3.598

8.  Effect of transoral incisionless fundoplication on reflux mechanisms.

Authors:  Nicolaas F Rinsma; Fabiënne G Smeets; Daisy W Bruls; Boudewijn F Kessing; Nicole D Bouvy; Ad A M Masclee; José M Conchillo
Journal:  Surg Endosc       Date:  2013-10-23       Impact factor: 4.584

9.  Feasibility of esophagogastric junction distensibility measurement during Nissen fundoplication.

Authors:  A Ilczyszyn; A J Botha
Journal:  Dis Esophagus       Date:  2013-08-30       Impact factor: 3.429

10.  The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial.

Authors:  George P Karamanolis; Stylianos Panopoulos; Konstantinos Denaxas; Anastasios Karlaftis; Alexandra Zorbala; Dimitrios Kamberoglou; Spiros D Ladas; Petros P Sfikakis
Journal:  Arthritis Res Ther       Date:  2016-09-01       Impact factor: 5.156

View more
  1 in total

1.  Fundic gastropexy for high risk of recurrence laparoscopic hiatal hernia repair and esophageal sphincter augmentation (LINX) improves outcomes without altering perioperative course.

Authors:  Robert Allman; James Speicher; Austin Rogers; Ethan Ledbetter; Aundrea Oliver; Mark Iannettoni; Carlos Anciano
Journal:  Surg Endosc       Date:  2020-07-17       Impact factor: 4.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.